Psoriasis: Treating to Target, How Do You Get There? Psoriasis: Treating to Target, How Do You Get There?
"With currently available treatment options, achieving complete or almost complete skin clearance is a very realistic outcome."Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 6, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Some MS Drugs Tied to Increased Psoriasis Risk Some MS Drugs Tied to Increased Psoriasis Risk
' People with MS and comorbid psoriasis may benefit from a careful consideration of disease-modifying therapy, specifically when B cell-depleting therapies are considered, ' said coauthor Ahmed Obeidat, MD.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 1, 2021 Category: Dermatology Tags: Neurology & Neurosurgery News Source Type: news

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [ACR] 20/50/70)a a...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Placebo Beat Risankizumab in Adults With Severe Asthma Placebo Beat Risankizumab in Adults With Severe Asthma
Risankizumab, a humanized, monoclonal antibody approved for the treatment of moderate to severe psoriasis, underperformed placebo in adults with severe asthma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 27, 2021 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Connected skin therapy company Zerigo Health scores $43M
Zerigo Health, formerly Clarify Medical, makes a connected phototherapy device for skin conditions like psoriasis, vitiligo  and eczema. (Source: mobihealthnews)
Source: mobihealthnews - October 21, 2021 Category: Information Technology Source Type: news

vTv Therapeutics Announces Deepa Prasad as New President and CEO
HIGH POINT, N.C., Oct. 20, 2021 -- (Healthcare Sales & Marketing Network) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, to... Biopharmaceuticals, Personnel vTv Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 20, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, ...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

What does YOUR dandruff say about your health?
Consultant dermatologist Dr Eva Melegh has identified the different types of dandruff, from small, white flakes caused by a burned scalp, to large silvery flakes that point to psoriasis. (Source: the Mail online | Health)
Source: the Mail online | Health - October 18, 2021 Category: Consumer Health News Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Common blood pressure pills taken by millions of Brits may raise the risk of psoriasis, study warns
A review of 21 studies by Korean researchers found common drugs ACE inhibitors, beta blockers, calcium channel blockers (CCBs) and thiazide diuretics, increased the risk of psoriasis. (Source: the Mail online | Health)
Source: the Mail online | Health - October 6, 2021 Category: Consumer Health News Source Type: news

Novel Topical Found Effective for Psoriasis in 52-Week Study Novel Topical Found Effective for Psoriasis in 52-Week Study
Benefits of treatment with tapinarof 1% were seen even with intermittent use in the extension trial.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 4, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
WESTLAKE VILLAGE, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 4, 2021 Category: Drugs & Pharmacology Source Type: news

First-in-Class TYK Inhibitor Shows Durable Effect for Psoriasis First-in-Class TYK Inhibitor Shows Durable Effect for Psoriasis
The 52-week data from two pivotal trials with deucravacitinib, a first-in-class inhibitor of tyrosine kinase 2 (TYK2), demonstrated durable control of moderate-to-severe plaque psoriasis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 1, 2021 Category: Dermatology Tags: Dermatology News Source Type: news